Back to Search Start Over

FCR holds up to the test of time: CLL8 follow-up.

Authors :
Woyach, Jennifer A.
Source :
Blood. 1/14/2016, Vol. 127 Issue 2, p172-173. 2p.
Publication Year :
2016

Abstract

The article discusses the follow up study on chronic lymphocytic leukemia (CLL)8 which uses fludarabine, cyclophosphamide, and rituximab (FCR) for initial therapy for CLL patients. Topics discussed include the paradigm of CLL therapy, the BCL2 inhibitor venetoclax trials, and the inappropriateness of FCR in the therapy.

Subjects

Subjects :
*CHRONIC lymphocytic leukemia
*CHRONIC lymphocytic leukemia treatment
*FLUDARABINE
*CYCLOPHOSPHAMIDE
*RITUXIMAB
*CLINICAL trials

Details

Language :
English
ISSN :
00064971
Volume :
127
Issue :
2
Database :
Academic Search Index
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
112862805
Full Text :
https://doi.org/10.1182/blood-2015-11-678557
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details